Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSE


Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (, a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdraw its shares from quotation on the OTCQB concurrent with listing its shares on the NYSE MKT.

“We welcome Provectus to the NYSE community and look forward to a strong partnership with the Company and its shareholders, ”Dr. Craig Dees, PhD, CEO of Provectus said, "Listing on the NYSE MKT is a huge milestone for Provectus Biopharmaceuticals, and I take a great deal of personal satisfaction from this news. I believe that this will enhance our shareholder value as well as broaden our shareholder base and heighten our corporate profile in the capital markets.”

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free